Ji Won Ha
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ji Won Ha has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
- Abhinav Kaushik
King Abdullah University of Science and Technology
1 shared publication - Adrian Hugenmatter
Sarafan ChEM-H, Stanford University, Stanford, USA
1 shared publication - Anne R. Waldrop
Department of Obstetrics and Gynecology Stanford University Palo Alto California USA
1 shared publication - Arvie Violette
Stanford Biophysics Program, Stanford University School of Medicine, Stanford, USA
1 shared publication - Ashley Utz
Stanford Biophysics Program, Stanford University School of Medicine, Stanford, USA
1 shared publication Carl Hanson
Center for Laboratory Sciences, California Department of Public Health, Richmond, USA
1 shared publication
Latest Publications
- Open Access
- 29 November 2025
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Development of ACE2-tropic-betacoronavirus therapeutics for future pandemic preparedness
A major challenge during viral pandemics is the ability to develop therapeutics whose efficacy can withstand viral genetic evolution. During the COVID-19 pandemic, five SARS-CoV-2 monoclonal antibody (mAb) therapeutics were rendered ineffective within a period of 2 years, leading to the U.S. FDA revoking their emergency use authorization. Here, we describe ReconnAb-multimers, a new therapeutic design that broadly and potently neutralize all tested betacoronaviruses that use host ACE2 as their receptor to enter cells. These ReconnAb-multimers have potent neutralization efficacy via avidity, enhanced breadth via a new pan-betacoronavirus-binding antibody that targets a highly conserved epitope on SARS-CoV-2 spike protein, and the potential for clinical development by using a catalytically inactive ACE2 component. We demonstrate that ReconnAb-multimers neutralize all SARS-CoV-2 pseudoviruses and authentic viral variants of concern (VOC) tested, with similar or higher potency than mAbs previously approved by the FDA; neutralize related pandemic-potential betacoronaviruses, including SARS-CoV, WIV1-CoV, PRD-0038, and merbecovirus HKU5-CoV-2; and despite a short half-life, protect female mice against authentic viral challenge with Omicron variant XBB.1.5. Our results highlight ReconnAb-multimers as a broad and highly potent therapeutic that could potentially withstand viral escape against current and future betacoronaviruses that require host ACE2 as a receptor.
- 29 November 2025
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessDevelopment of ACE2-tropic-betacoronavirus therapeutics for future pandemic preparedness
A major challenge during viral pandemics is the ability to develop therapeutics whose efficacy can withstand viral genetic evolution. During the COVID-19 pandemic, five SARS-CoV-2 monoclonal antibody (mAb) therapeutics were rendered ineffective within a period of 2 years, leading to the U.S. FDA revoking their emergency use authorization. Here, we describe ReconnAb-multimers, a new therapeutic design that broadly and potently neutralize all tested betacoronaviruses that use host ACE2 as their receptor to enter cells. These ReconnAb-multimers have potent neutralization efficacy via avidity, enhanced breadth via a new pan-betacoronavirus-binding antibody that targets a highly conserved epitope on SARS-CoV-2 spike protein, and the potential for clinical development by using a catalytically inactive ACE2 component. We demonstrate that ReconnAb-multimers neutralize all SARS-CoV-2 pseudoviruses and authentic viral variants of concern (VOC) tested, with similar or higher potency than mAbs previously approved by the FDA; neutralize related pandemic-potential betacoronaviruses, including SARS-CoV, WIV1-CoV, PRD-0038, and merbecovirus HKU5-CoV-2; and despite a short half-life, protect female mice against authentic viral challenge with Omicron variant XBB.1.5. Our results highlight ReconnAb-multimers as a broad and highly potent therapeutic that could potentially withstand viral escape against current and future betacoronaviruses that require host ACE2 as a receptor.
- Open Access
- 29 November 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 10 (48) , eadp5227
Impact of air pollution exposure on cytokines and histone modification profiles at single-cell levels during pregnancy
Fine particulate matter (PM 2.5 ) exposure can induce immune system pathology via epigenetic modification, affecting pregnancy outcomes. Our study investigated the association between PM 2.5 exposure and immune response, as well as epigenetic changes using high-dimensional epigenetic landscape profiling using cytometry by time-of-flight (EpiTOF) at the single cell. We found statistically significant associations between PM 2.5 exposure and levels of certain cytokines [interleukin-1RA (IL-1RA), IL-8/CXCL8, IL-18, and IL-27)] and histone posttranslational modifications (HPTMs) in immune cells (HPTMs: H3K9ac, H3K23ac, H3K27ac, H2BK120ub, H4K20me1/3, and H3K9me1/2) among pregnant and nonpregnant women. The cord blood of neonates with high maternal PM 2.5 exposure showed lower IL-27 than those with low exposure. Furthermore, PM 2.5 exposure affects the co-modification profiles of cytokines between pregnant women and their neonates, along with HPTMs in each immune cell type between pregnant and nonpregnant women. These modifications in specific histones and cytokines could indicate the toxicological mechanism of PM 2.5 exposure in inflammation, inflammasome pathway, and pregnancy complications.
- 29 November 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 10 (48) , eadp5227
Open AccessImpact of air pollution exposure on cytokines and histone modification profiles at single-cell levels during pregnancy
Fine particulate matter (PM 2.5 ) exposure can induce immune system pathology via epigenetic modification, affecting pregnancy outcomes. Our study investigated the association between PM 2.5 exposure and immune response, as well as epigenetic changes using high-dimensional epigenetic landscape profiling using cytometry by time-of-flight (EpiTOF) at the single cell. We found statistically significant associations between PM 2.5 exposure and levels of certain cytokines [interleukin-1RA (IL-1RA), IL-8/CXCL8, IL-18, and IL-27)] and histone posttranslational modifications (HPTMs) in immune cells (HPTMs: H3K9ac, H3K23ac, H3K27ac, H2BK120ub, H4K20me1/3, and H3K9me1/2) among pregnant and nonpregnant women. The cord blood of neonates with high maternal PM 2.5 exposure showed lower IL-27 than those with low exposure. Furthermore, PM 2.5 exposure affects the co-modification profiles of cytokines between pregnant women and their neonates, along with HPTMs in each immune cell type between pregnant and nonpregnant women. These modifications in specific histones and cytokines could indicate the toxicological mechanism of PM 2.5 exposure in inflammation, inflammasome pathway, and pregnancy complications.